<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32784556</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>07</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1158</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom10081158</ELocationID><Abstract><AbstractText>Neurodegenerative diseases are the second most common cause of death and characterized by progressive impairments in movement or mental functioning in the central or peripheral nervous system. The prevention of neurodegenerative disorders has become an emerging public health challenge for our society. Melatonin, a pineal hormone, has various physiological functions in the brain, including regulating circadian rhythms, clearing free radicals, inhibiting biomolecular oxidation, and suppressing neuroinflammation. Cumulative evidence indicates that melatonin has a wide range of neuroprotective roles by regulating pathophysiological mechanisms and signaling pathways. Moreover, melatonin levels are decreased in patients with neurodegenerative diseases. In this review, we summarize current knowledge on the regulation, molecular mechanisms and biological functions of melatonin in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, vascular dementia and multiple sclerosis. We also discuss the clinical application of melatonin in neurodegenerative disorders. This information will lead to a better understanding of the regulation of melatonin in the brain and provide therapeutic options for the treatment of various neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Dongmei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Tae Ho</ForeName><Initials>TH</Initials><Identifier Source="ORCID">0000-0001-5968-1478</Identifier><AffiliationInfo><Affiliation>Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350122, Fujian, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81901071</GrantID><Agency>National Natural Science Foundation of China</Agency><Country>International</Country></Grant><Grant><GrantID>81970993</GrantID><Agency>National Natural Science Foundation of China</Agency><Country>International</Country></Grant><Grant><GrantID>2019J01297</GrantID><Agency>Natural Science Foundation of Fujian Province</Agency><Country>International</Country></Grant><Grant><GrantID>2019J05072</GrantID><Agency>Natural Science Foundation of Fujian Province</Agency><Country>International</Country></Grant><Grant><GrantID>2019-CX-36</GrantID><Agency>Medical Innovation Grant of Fujian Province</Agency><Country>International</Country></Grant><Grant><GrantID>XRCZX2017007</GrantID><Agency>Fujian Medical University</Agency><Country>International</Country></Grant><Grant><GrantID>XRCZX2017019</GrantID><Agency>Fujian Medical University</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>JL5DK93RCL</RegistryNumber><NameOfSubstance UI="D008550">Melatonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="Y">Circadian Rhythm</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008550" MajorTopicYN="N">Melatonin</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Huntington&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">melatonin</Keyword><Keyword MajorTopicYN="N">neurodegenerative disease</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32784556</ArticleId><ArticleId IdType="pmc">PMC7464852</ArticleId><ArticleId IdType="doi">10.3390/biom10081158</ArticleId><ArticleId IdType="pii">biom10081158</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lerner A.B., Case J.D., Takahashi Y., Lee T.H., Mori W. Isolation of melatonin, the pineal gland factor that lightens melanocytes1. J. Am. Chem. Soc. 1958;80:2587. doi: 10.1021/ja01543a060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja01543a060</ArticleId></ArticleIdList></Reference><Reference><Citation>Claustrat B., Brun J., Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med. Rev. 2005;9:11&#x2013;24. doi: 10.1016/j.smrv.2004.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smrv.2004.08.001</ArticleId><ArticleId IdType="pubmed">15649735</ArticleId></ArticleIdList></Reference><Reference><Citation>Slats D., Claassen J.A., Verbeek M.M., Overeem S. Reciprocal interactions between sleep, circadian rhythms and alzheimer&#x2019;s disease: Focus on the role of hypocretin and melatonin. Ageing Res. Rev. 2013;12:188&#x2013;200. doi: 10.1016/j.arr.2012.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2012.04.003</ArticleId><ArticleId IdType="pubmed">22575905</ArticleId></ArticleIdList></Reference><Reference><Citation>Vriend J., Reiter R.J. Melatonin feedback on clock genes: A theory involving the proteasome. J. Pineal Res. 2015;58:1&#x2013;11. doi: 10.1111/jpi.12189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12189</ArticleId><ArticleId IdType="pubmed">25369242</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter R.J., Rosales-Corral S.A., Tan D.X., Acuna-Castroviejo D., Qin L., Yang S.F., Xu K. Melatonin, a full service anti-cancer agent: Inhibition of initiation, progression and metastasis. Int. J. Mol. Sci. 2017;18:843. doi: 10.3390/ijms18040843.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18040843</ArticleId><ArticleId IdType="pmc">PMC5412427</ArticleId><ArticleId IdType="pubmed">28420185</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali D.P. Melatonin: Clinical perspectives in neurodegeneration. Front. Endocrinol. 2019;10:480. doi: 10.3389/fendo.2019.00480.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2019.00480</ArticleId><ArticleId IdType="pmc">PMC6646522</ArticleId><ArticleId IdType="pubmed">31379746</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R., Wang X., Ni L., Di X., Ma B., Niu S., Liu C., Reiter R.J. Covid-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020;250:117583. doi: 10.1016/j.lfs.2020.117583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117583</ArticleId><ArticleId IdType="pmc">PMC7102583</ArticleId><ArticleId IdType="pubmed">32217117</ArticleId></ArticleIdList></Reference><Reference><Citation>Talib W.H. Melatonin and cancer hallmarks. Molecules. 2018;23:518. doi: 10.3390/molecules23030518.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules23030518</ArticleId><ArticleId IdType="pmc">PMC6017729</ArticleId><ArticleId IdType="pubmed">29495398</ArticleId></ArticleIdList></Reference><Reference><Citation>Gan L., Cookson M.R., Petrucelli L., La Spada A.R. Converging pathways in neurodegeneration, from genetics to mechanisms. Nat. Neurosci. 2018;21:1300&#x2013;1309. doi: 10.1038/s41593-018-0237-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0237-7</ArticleId><ArticleId IdType="pmc">PMC6278826</ArticleId><ArticleId IdType="pubmed">30258237</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunata M., Parlakpinar H., Acet H.A. Melatonin: A review of its potential functions and effects on neurological diseases. Revue Neurol. 2020;176:148&#x2013;165. doi: 10.1016/j.neurol.2019.07.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2019.07.025</ArticleId><ArticleId IdType="pubmed">31718830</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter R.J. Pineal melatonin: Cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 1991;12:151&#x2013;180. doi: 10.1210/edrv-12-2-151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/edrv-12-2-151</ArticleId><ArticleId IdType="pubmed">1649044</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokkan K.A., Reiter R.J. Melatonin rhythms in arctic urban residents. J. Pineal Res. 1994;16:33&#x2013;36. doi: 10.1111/j.1600-079X.1994.tb00079.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.1994.tb00079.x</ArticleId><ArticleId IdType="pubmed">8158521</ArticleId></ArticleIdList></Reference><Reference><Citation>Benot S., Molinero P., Soutto M., Goberna R., Guerrero J.M. Circadian variations in the rat serum total antioxidant status: Correlation with melatonin levels. J. Pineal Res. 1998;25:1&#x2013;4. doi: 10.1111/j.1600-079X.1998.tb00378.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.1998.tb00378.x</ArticleId><ArticleId IdType="pubmed">9694397</ArticleId></ArticleIdList></Reference><Reference><Citation>He R., Cui M., Lin H., Zhao L., Wang J., Chen S., Shao Z. Melatonin resists oxidative stress-induced apoptosis in nucleus pulposus cells. Life Sci. 2018;199:122&#x2013;130. doi: 10.1016/j.lfs.2018.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2018.03.020</ArticleId><ArticleId IdType="pubmed">29526797</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter R.J., Tan D.X., Erren T.C., Fuentes-Broto L., Paredes S.D. Light-mediated perturbations of circadian timing and cancer risk: A mechanistic analysis. Integr. Cancer Ther. 2009;8:354&#x2013;360. doi: 10.1177/1534735409352026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1534735409352026</ArticleId><ArticleId IdType="pubmed">20042411</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta M., Gupta Y.K., Agarwal S., Aneja S., Kalaivani M., Kohli K. Effects of add-on melatonin administration on antioxidant enzymes in children with epilepsy taking carbamazepine monotherapy: A randomized, double-blind, placebo-controlled trial. Epilepsia. 2004;45:1636&#x2013;1639. doi: 10.1111/j.0013-9580.2004.17604.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0013-9580.2004.17604.x</ArticleId><ArticleId IdType="pubmed">15571523</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez C., Mayo J.C., Sainz R.M., Antol&#xed;n I., Herrera F., Mart&#xed;n V., Reiter R.J. Regulation of antioxidant enzymes: A significant role for melatonin. J. Pineal Res. 2004;36:1&#x2013;9. doi: 10.1046/j.1600-079X.2003.00092.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1600-079X.2003.00092.x</ArticleId><ArticleId IdType="pubmed">14675124</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirata F., Hayaishi O., Tokuyama T., Seno S. In vitro and in vivo formation of two new metabolites of melatonin. J. Biol. Chem. 1974;249:1311&#x2013;1313.</Citation><ArticleIdList><ArticleId IdType="pubmed">4814344</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosales-Corral S., Tan D.X., Reiter R.J., Valdivia-Vel&#xe1;zquez M., Mart&#xed;nez-Barboza G., Acosta-Mart&#xed;nez J.P., Ortiz G.G. Orally administered melatonin reduces oxidative stress and proinflammatory cytokines induced by amyloid-beta peptide in rat brain: A comparative, in vivo study versus vitamin c and e. J. Pineal Res. 2003;35:80&#x2013;84. doi: 10.1034/j.1600-079X.2003.00057.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-079X.2003.00057.x</ArticleId><ArticleId IdType="pubmed">12887649</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota O., Terada S., Ishizu H., Ishihara T., Ujike H., Nakashima H., Nakashima Y., Kugo A., Checler F., Kuroda S. Cyclooxygenase-2 in the hippocampus is up-regulated in alzheimer&#x2019;s disease but not in variant alzheimer&#x2019;s disease with cotton wool plaques in humans. Neurosci. Lett. 2003;343:175&#x2013;179. doi: 10.1016/S0304-3940(03)00339-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(03)00339-2</ArticleId><ArticleId IdType="pubmed">12770691</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang M.H., Jung S.B., Lee M.H., Kim C.J., Oh Y.T., Kang I., Kim J., Kim E.H. Melatonin attenuates amyloid beta25-35-induced apoptosis in mouse microglial bv2 cells. Neurosci. Lett. 2005;380:26&#x2013;31. doi: 10.1016/j.neulet.2005.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2005.01.003</ArticleId><ArticleId IdType="pubmed">15854745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Xiao X., Zhang Y., Shi D., Chen W., Fu L., Liu L., Xie F., Kang T., Huang W., et al. Simultaneous modulation of cox-2, p300, akt, and apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J. Pineal Res. 2012;53:77&#x2013;90. doi: 10.1111/j.1600-079X.2012.00973.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2012.00973.x</ArticleId><ArticleId IdType="pubmed">22335196</ArticleId></ArticleIdList></Reference><Reference><Citation>Men&#xe9;ndez-Men&#xe9;ndez J., Hermida-Prado F. Deciphering the molecular basis of melatonin protective effects on breast cells treated with doxorubicin: Twist1 a transcription factor involved in emt and metastasis, a novel target of melatonin. Cancers. 2019;11:1011. doi: 10.3390/cancers11071011.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11071011</ArticleId><ArticleId IdType="pmc">PMC6679136</ArticleId><ArticleId IdType="pubmed">31331001</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekmekcioglu C. Melatonin receptors in humans: Biological role and clinical relevance. Biomed. Pharmacother. 2006;60:97&#x2013;108. doi: 10.1016/j.biopha.2006.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2006.01.002</ArticleId><ArticleId IdType="pubmed">16527442</ArticleId></ArticleIdList></Reference><Reference><Citation>Emet M., Ozcan H., Yayla M., Halici Z., Hacimuftuoglu A. A review of melatonin, its receptors and drugs. Eurasian J. Med. 2016;48:135. doi: 10.5152/eurasianjmed.2015.0267.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/eurasianjmed.2015.0267</ArticleId><ArticleId IdType="pmc">PMC4970552</ArticleId><ArticleId IdType="pubmed">27551178</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandi-Perumal S.R., Trakht I., Srinivasan V., Spence D.W., Maestroni G.J., Zisapel N., Cardinali D.P. Physiological effects of melatonin: Role of melatonin receptors and signal transduction pathways. Prog. Neurobiol. 2008;85:335&#x2013;353. doi: 10.1016/j.pneurobio.2008.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2008.04.001</ArticleId><ArticleId IdType="pubmed">18571301</ArticleId></ArticleIdList></Reference><Reference><Citation>Comai S., Gobbi G. Unveiling the role of melatonin mt2 receptors in sleep, anxiety and other neuropsychiatric diseases: A novel target in psychopharmacology. J. Psychiatry Neurosci. JPN. 2014;39:6&#x2013;21. doi: 10.1503/jpn.130009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/jpn.130009</ArticleId><ArticleId IdType="pmc">PMC3868666</ArticleId><ArticleId IdType="pubmed">23971978</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosjean O., Ferro M., Coge F., Beauverger P., Henlin J.M., Lefoulon F., Fauchere J.L., Delagrange P., Canet E., Boutin J.A. Identification of the melatonin-binding site mt3 as the quinone reductase 2. J. Biol. Chem. 2000;275:31311&#x2013;31317. doi: 10.1074/jbc.M005141200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M005141200</ArticleId><ArticleId IdType="pubmed">10913150</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlberg C. Gene regulation by melatonin. Ann. N. Y. Acad. Sci. 2000;917:387&#x2013;396. doi: 10.1111/j.1749-6632.2000.tb05403.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2000.tb05403.x</ArticleId><ArticleId IdType="pubmed">11268365</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia J.A., Volt H., Venegas C., Doerrier C., Escames G., Lopez L.C., Acuna-Castroviejo D. Disruption of the nf-kappab/nlrp3 connection by melatonin requires retinoid-related orphan receptor-alpha and blocks the septic response in mice. FASEB J. 2015;29:3863&#x2013;3875. doi: 10.1096/fj.15-273656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.15-273656</ArticleId><ArticleId IdType="pubmed">26045547</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali D.P., Freire F. Melatonin effects on brain. Interaction with microtubule protein, inhibition of fast axoplasmic flow and induction of crystaloid and tubular formations in the hypothalamus. Mol. Cell. Endocrinol. 1975;2:317&#x2013;330. doi: 10.1016/0303-7207(75)90019-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0303-7207(75)90019-2</ArticleId><ArticleId IdType="pubmed">47820</ArticleId></ArticleIdList></Reference><Reference><Citation>Melendez J., Maldonado V., Ortega A. Effect of melatonin on beta-tubulin and map2 expression in nie-115 cells. Neurochem. Res. 1996;21:653&#x2013;658. doi: 10.1007/BF02527721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02527721</ArticleId><ArticleId IdType="pubmed">8829136</ArticleId></ArticleIdList></Reference><Reference><Citation>Macias M., Escames G., Leon J., Coto A., Sbihi Y., Osuna A., Acuna-Castroviejo D. Calreticulin-melatonin. An unexpected relationship. Eur. J. Biochem. 2003;270:832&#x2013;840. doi: 10.1046/j.1432-1033.2003.03430.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1432-1033.2003.03430.x</ArticleId><ArticleId IdType="pubmed">12603316</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez-King G., Anton-Tay F. Calmodulin mediates melatonin cytoskeletal effects. Experientia. 1993;49:635&#x2013;641. doi: 10.1007/BF01923944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01923944</ArticleId><ArticleId IdType="pubmed">8359270</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez-King G., Huerto-Delgadillo L., Anton-Tay F. Melatonin modifies calmodulin cell levels in mdck and n1e-115 cell lines and inhibits phosphodiesterase activity in vitro. Brain Res. 1991;557:289&#x2013;292. doi: 10.1016/0006-8993(91)90146-M.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(91)90146-M</ArticleId><ArticleId IdType="pubmed">1747759</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez-King G., Rios A., Martinez A., Anton-Tay F. In vitro inhibition of ca2+/calmodulin-dependent kinase ii activity by melatonin. Biochim. Biophys. Acta. 1996;1290:191&#x2013;196. doi: 10.1016/0304-4165(96)00025-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-4165(96)00025-6</ArticleId><ArticleId IdType="pubmed">8645723</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenwitheesuk A., Nopparat C., Mukda S., Wongchitrat P., Govitrapong P. Melatonin regulates aging and neurodegeneration through energy metabolism, epigenetics, autophagy and circadian rhythm pathways. Int. J. Mol. Sci. 2014;15:16848&#x2013;16884. doi: 10.3390/ijms150916848.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms150916848</ArticleId><ArticleId IdType="pmc">PMC4200827</ArticleId><ArticleId IdType="pubmed">25247581</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter R.J., Tan D.X., Manchester L.C., Pilar Terron M., Flores L.J., Koppisepi S. Medical implications of melatonin: Receptor-mediated and receptor-independent actions. Adv. Med. Sci. 2007;52:11&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">18217386</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter R.J. The pineal gland and melatonin in relation to aging: A summary of the theories and of the data. Exp. Gerontol. 1995;30:199&#x2013;212. doi: 10.1016/0531-5565(94)00045-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0531-5565(94)00045-5</ArticleId><ArticleId IdType="pubmed">7556503</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter R.J., Tan D.X., Poeggeler B., Menendez-Pelaez A., Chen L.D., Saarela S. Melatonin as a free radical scavenger: Implications for aging and age-related diseases. Ann. N. Y. Acad. Sci. 1994;719:1&#x2013;12. doi: 10.1111/j.1749-6632.1994.tb56817.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1994.tb56817.x</ArticleId><ArticleId IdType="pubmed">8010585</ArticleId></ArticleIdList></Reference><Reference><Citation>Weishaupt J.H., Bartels C., Polking E., Dietrich J., Rohde G., Poeggeler B., Mertens N., Sperling S., Bohn M., Huther G., et al. Reduced oxidative damage in als by high-dose enteral melatonin treatment. J. Pineal Res. 2006;41:313&#x2013;323. doi: 10.1111/j.1600-079X.2006.00377.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2006.00377.x</ArticleId><ArticleId IdType="pubmed">17014688</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter R.J., Tan D.X., Sainz R.M., Mayo J.C., Lopez-Burillo S. Melatonin: Reducing the toxicity and increasing the efficacy of drugs. J. Pharm. Pharmacol. 2002;54:1299&#x2013;1321. doi: 10.1211/002235702760345374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1211/002235702760345374</ArticleId><ArticleId IdType="pubmed">12396291</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in alzheimer&#x2019;s disease and related disorders. Nat. Rev. Neurosci. 2007;8:663&#x2013;672. doi: 10.1038/nrn2194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2194</ArticleId><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Selkoe D.J. The amyloid hypothesis of alzheimer&#x2019;s disease: Progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356. doi: 10.1126/science.1072994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C.R.J., Holtzman D.M. Biomarker modeling of alzheimer&#x2019;s disease. Neuron. 2013;80:1347&#x2013;1358. doi: 10.1016/j.neuron.2013.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.003</ArticleId><ArticleId IdType="pmc">PMC3928967</ArticleId><ArticleId IdType="pubmed">24360540</ArticleId></ArticleIdList></Reference><Reference><Citation>Polanco J.C., Li C., Bodea L.G., Martinez-Marmol R., Meunier F.A., Gotz J. Amyloid-beta and tau complexity-towards improved biomarkers and targeted therapies. Nat. Rev. Neurol. 2018;14:22&#x2013;39. doi: 10.1038/nrneurol.2017.162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2017.162</ArticleId><ArticleId IdType="pubmed">29242522</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones T.L., Hyman B.T. The intersection of amyloid beta and tau at synapses in alzheimer&#x2019;s disease. Neuron. 2014;82:756&#x2013;771. doi: 10.1016/j.neuron.2014.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.05.004</ArticleId><ArticleId IdType="pmc">PMC4135182</ArticleId><ArticleId IdType="pubmed">24853936</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y.H., Swaab D.F. The human pineal gland and melatonin in aging and alzheimer&#x2019;s disease. J. Pineal Res. 2005;38:145&#x2013;152. doi: 10.1111/j.1600-079X.2004.00196.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2004.00196.x</ArticleId><ArticleId IdType="pubmed">15725334</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y.H., Feenstra M.G., Zhou J.N., Liu R.Y., Torano J.S., Van Kan H.J., Fischer D.F., Ravid R., Swaab D.F. Molecular changes underlying reduced pineal melatonin levels in alzheimer disease: Alterations in preclinical and clinical stages. J. Clin. Endocrinol. Metab. 2003;88:5898&#x2013;5906. doi: 10.1210/jc.2003-030833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2003-030833</ArticleId><ArticleId IdType="pubmed">14671188</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J.N., Liu R.Y., Kamphorst W., Hofman M.A., Swaab D.F. Early neuropathological alzheimer&#x2019;s changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J. Pineal Res. 2003;35:125&#x2013;130. doi: 10.1034/j.1600-079X.2003.00065.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-079X.2003.00065.x</ArticleId><ArticleId IdType="pubmed">12887656</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahlberg R., Kunz D., Sutej I., Kuhl K.P., Hellweg R. Melatonin treatment of day-night rhythm disturbances and sundowning in alzheimer disease: An open-label pilot study using actigraphy. J. Clin. Psychopharmacol. 2004;24:456&#x2013;459. doi: 10.1097/01.jcp.0000132443.12607.fd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.jcp.0000132443.12607.fd</ArticleId><ArticleId IdType="pubmed">15232344</ArticleId></ArticleIdList></Reference><Reference><Citation>Brusco L.I., Marquez M., Cardinali D.P. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in alzheimer&#x2019;s disease. Neuro Endocrinol. Lett. 2000;21:39&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">11455329</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Chen D., Lee T.H. Phosphorylation signaling in app processing in alzheimer&#x2019;s disease. Int. J. Mol. Sci. 2020;21:209. doi: 10.3390/ijms21010209.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21010209</ArticleId><ArticleId IdType="pmc">PMC6981488</ArticleId><ArticleId IdType="pubmed">31892243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiri D.K. Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types. J. Pineal Res. 1999;26:137&#x2013;146. doi: 10.1111/j.1600-079X.1999.tb00575.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.1999.tb00575.x</ArticleId><ArticleId IdType="pubmed">10231726</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X.C., Zhang Y.C., Chatterjie N., Grundke-Iqbal I., Iqbal K., Wang J.Z. Effect of melatonin and melatonylvalpromide on beta-amyloid and neurofilaments in n2a cells. Neurochem. Res. 2008;33:1138&#x2013;1144. doi: 10.1007/s11064-007-9563-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-007-9563-y</ArticleId><ArticleId IdType="pubmed">18231852</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.C., Wang Z.F., Wang Q., Wang Y.P., Wang J.Z. Melatonin attenuates beta-amyloid-induced inhibition of neurofilament expression. Acta Pharmacol. Sin. 2004;25:447&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">15066211</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinchalongporn V., Shukla M., Govitrapong P. Melatonin ameliorates abeta42 -induced alteration of betaapp-processing secretases via the melatonin receptor through the pin1/gsk3beta/nf-kappab pathway in sh-sy5y cells. J. Pineal Res. 2018;64:e12470. doi: 10.1111/jpi.12470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12470</ArticleId><ArticleId IdType="pubmed">29352484</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappolla M., Bozner P., Soto C., Shao H., Robakis N.K., Zagorski M., Frangione B., Ghiso J. Inhibition of alzheimer beta-fibrillogenesis by melatonin. J. Biol. Chem. 1998;273:7185&#x2013;7188. doi: 10.1074/jbc.273.13.7185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.13.7185</ArticleId><ArticleId IdType="pubmed">9516407</ArticleId></ArticleIdList></Reference><Reference><Citation>Poeggeler B., Miravalle L., Zagorski M.G., Wisniewski T., Chyan Y.J., Zhang Y., Shao H., Bryant-Thomas T., Vidal R., Frangione B., et al. Melatonin reverses the profibrillogenic activity of apolipoprotein e4 on the alzheimer amyloid abeta peptide. Biochemistry. 2001;40:14995&#x2013;15001. doi: 10.1021/bi0114269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi0114269</ArticleId><ArticleId IdType="pubmed">11732920</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z., Zhang J.T. Long-term melatonin or 17beta-estradiol supplementation alleviates oxidative stress in ovariectomized adult rats. Free Radic. Biol. Med. 2005;39:195&#x2013;204. doi: 10.1016/j.freeradbiomed.2005.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2005.03.007</ArticleId><ArticleId IdType="pubmed">15964511</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoppe J.B., Frozza R.L., Horn A.P., Comiran R.A., Bernardi A., Campos M.M., Battastini A.M., Salbego C. Amyloid-beta neurotoxicity in organotypic culture is attenuated by melatonin: Involvement of gsk-3beta, tau and neuroinflammation. J. Pineal Res. 2010;48:230&#x2013;238. doi: 10.1111/j.1600-079X.2010.00747.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2010.00747.x</ArticleId><ArticleId IdType="pubmed">20136701</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali T., Kim M.O. Melatonin ameliorates amyloid beta-induced memory deficits, tau hyperphosphorylation and neurodegeneration via pi3/akt/gsk3&#x3b2; pathway in the mouse hippocampus. J. Pineal Res. 2015;59:47&#x2013;59. doi: 10.1111/jpi.12238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12238</ArticleId><ArticleId IdType="pubmed">25858697</ArticleId></ArticleIdList></Reference><Reference><Citation>Peineau S., Taghibiglou C., Bradley C., Wong T.P., Liu L., Lu J., Lo E., Wu D., Saule E., Bouschet T., et al. Ltp inhibits ltd in the hippocampus via regulation of gsk3beta. Neuron. 2007;53:703&#x2013;717. doi: 10.1016/j.neuron.2007.01.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.029</ArticleId><ArticleId IdType="pubmed">17329210</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo J., Whitcomb D.J., Olsen K.M., Kerrigan T.L., Lo S.C., Bru-Mercier G., Dickinson B., Scullion S., Sheng M., Collingridge G., et al. A&#x3b2;(1-42) inhibition of ltp is mediated by a signaling pathway involving caspase-3, akt1 and gsk-3&#x3b2;. Nat. Neurosci. 2011;14:545&#x2013;547. doi: 10.1038/nn.2785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2785</ArticleId><ArticleId IdType="pubmed">21441921</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.Y., Koh S.H., Noh M.Y., Kim S.H., Lee Y.J. Phosphatidylinositol-3-kinase activation blocks amyloid beta-induced neurotoxicity. Toxicology. 2008;243:43&#x2013;50. doi: 10.1016/j.tox.2007.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tox.2007.09.020</ArticleId><ArticleId IdType="pubmed">17980476</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones T.L., Stoothoff W.H., de Calignon A., Jones P.B., Hyman B.T. Tau pathophysiology in neurodegeneration: A tangled issue. Trends NeuroSci. 2009;32:150&#x2013;159. doi: 10.1016/j.tins.2008.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2008.11.007</ArticleId><ArticleId IdType="pubmed">19162340</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S.P., Deng Y.Q., Wang X.C., Wang Y.P., Wang J.Z. Melatonin protects sh-sy5y neuroblastoma cells from calyculin a-induced neurofilament impairment and neurotoxicity. J. Pineal Res. 2004;36:186&#x2013;191. doi: 10.1111/j.1600-079X.2004.00116.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2004.00116.x</ArticleId><ArticleId IdType="pubmed">15009509</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X., Yang Y., Fu Z., Li Y., Feng J., Luo J., Zhang Q., Wang Q., Tian Q. Melatonin ameliorates alzheimer-like pathological changes and spatial memory retention impairment induced by calyculin a. J. Psychopharmacol. 2011;25:1118&#x2013;1125. doi: 10.1177/0269881110367723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881110367723</ArticleId><ArticleId IdType="pubmed">20542922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling Z.Q., Tian Q., Wang L., Fu Z.Q., Wang X.C., Wang Q., Wang J.Z. Constant illumination induces alzheimer-like damages with endoplasmic reticulum involvement and the protection of melatonin. J. Alzheimers Dis. 2009;16:287&#x2013;300. doi: 10.3233/JAD-2009-0949.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2009-0949</ArticleId><ArticleId IdType="pubmed">19221418</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi C., Zeng J., Li Z., Chen Q., Hang W., Xia L., Wu Y., Chen J., Shi A. Melatonin mitigates kainic acid-induced neuronal tau hyperphosphorylation and memory deficits through alleviating er stress. Front. Mol. Neurosci. 2018;11:5. doi: 10.3389/fnmol.2018.00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00005</ArticleId><ArticleId IdType="pmc">PMC5787934</ArticleId><ArticleId IdType="pubmed">29416502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D.L., Ling Z.Q., Cao F.Y., Zhu L.Q., Wang J.Z. Melatonin attenuates isoproterenol-induced protein kinase a overactivation and tau hyperphosphorylation in rat brain. J. Pineal Res. 2004;37:11&#x2013;16. doi: 10.1111/j.1600-079X.2004.00130.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2004.00130.x</ArticleId><ArticleId IdType="pubmed">15230863</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y.Q., Xu G.G., Duan P., Zhang Q., Wang J.Z. Effects of melatonin on wortmannin-induced tau hyperphosphorylation. Acta Pharmacol. Sin. 2005;26:519&#x2013;526. doi: 10.1111/j.1745-7254.2005.00102.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1745-7254.2005.00102.x</ArticleId><ArticleId IdType="pubmed">15842767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I., Gomez-Isla T., Puig B., Freixes M., Rib&#xe9; E., Dalf&#xf3; E., Avila J. Current advances on different kinases involved in tau phosphorylation, and implications in alzheimer&#x2019;s disease and tauopathies. Curr. Alzheimer Res. 2005;2:3&#x2013;18. doi: 10.2174/1567205052772713.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205052772713</ArticleId><ArticleId IdType="pubmed">15977985</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng C.X., Hu J., Liu D., Hong X.P., Wu Y.Y., Zhu L.Q., Wang J.Z. Disease-modified glycogen synthase kinase-3&#x3b2; intervention by melatonin arrests the pathology and memory deficits in an alzheimer&#x2019;s animal model. Neurobiol. Aging. 2013;34:1555&#x2013;1563. doi: 10.1016/j.neurobiolaging.2012.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.12.010</ArticleId><ArticleId IdType="pubmed">23402899</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Zhu L., Shi H., Zheng H., Tian Q., Wang Q., Liu R., Wang J.Z. Inhibition of melatonin biosynthesis induces neurofilament hyperphosphorylation with activation of cyclin-dependent kinase 5. Neurochem. Res. 2007;32:1329&#x2013;1335. doi: 10.1007/s11064-007-9308-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-007-9308-y</ArticleId><ArticleId IdType="pubmed">17401652</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera-Bermudez M.A., Gerdin M.J., Earnest D.J., Dubocovich M.L. Regulation of basal rhythmicity in protein kinase c activity by melatonin in immortalized rat suprachiasmatic nucleus cells. Neurosci. Lett. 2003;346:37&#x2013;40. doi: 10.1016/S0304-3940(03)00590-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(03)00590-1</ArticleId><ArticleId IdType="pubmed">12850542</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X.C., Wang Z.F., Zhang J.X., Wang Q., Wang J.Z. Effect of melatonin on calyculin a-induced tau hyperphosphorylation. Eur. J. Pharmacol. 2005;510:25&#x2013;30. doi: 10.1016/j.ejphar.2005.01.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2005.01.023</ArticleId><ArticleId IdType="pubmed">15740721</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L.Q., Wang S.H., Ling Z.Q., Wang D.L., Wang J.Z. Effect of inhibiting melatonin biosynthesis on spatial memory retention and tau phosphorylation in rat. J. Pineal Res. 2004;37:71&#x2013;77. doi: 10.1111/j.1600-079X.2004.00136.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2004.00136.x</ArticleId><ArticleId IdType="pubmed">15298664</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvira D., Tajes M., Verdaguer E., Acu&#xf1;a-Castroviejo D., Folch J., Camins A., Pallas M. Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of parkinson&#x2019;s disease. J. Pineal Res. 2006;40:251&#x2013;258. doi: 10.1111/j.1600-079X.2005.00308.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2005.00308.x</ArticleId><ArticleId IdType="pubmed">16499562</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D., Mei Y., Kim N., Lan G., Gan C.L., Fan F., Zhang T., Xia Y., Wang L., Lin C., et al. Melatonin directly binds and inhibits death-associated protein kinase 1 function in alzheimer&#x2019;s disease. J. Pineal Res. 2020;69:e12665. doi: 10.1111/jpi.12665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12665</ArticleId><ArticleId IdType="pubmed">32358852</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim N., Chen D., Zhou X.Z., Lee T.H. Death-associated protein kinase 1 phosphorylation in neuronal cell death and neurodegenerative disease. Int. J. Mol. Sci. 2019;20:3131. doi: 10.3390/ijms20133131.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20133131</ArticleId><ArticleId IdType="pmc">PMC6651373</ArticleId><ArticleId IdType="pubmed">31248062</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D., Zhou X.Z., Lee T.H. Death-associated protein kinase 1 as a promising drug target in cancer and alzheimer&#x2019;s disease. Recent Pat. Anti Cancer Drug Discov. 2019;14:144&#x2013;157. doi: 10.2174/1574892814666181218170257.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1574892814666181218170257</ArticleId><ArticleId IdType="pmc">PMC6751350</ArticleId><ArticleId IdType="pubmed">30569876</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D., Wang L., Lee T.H. Post-translational modifications of the peptidyl-prolyl isomerase pin1. Front. Cell Dev. Biol. 2020;8:129. doi: 10.3389/fcell.2020.00129.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.00129</ArticleId><ArticleId IdType="pmc">PMC7064559</ArticleId><ArticleId IdType="pubmed">32195254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Zhou Y., Chen D., Lee T.H. Peptidyl-prolyl cis/trans isomerase pin1 and alzheimer&#x2019;s disease. Front. Cell Dev. Biol. 2020;8:355. doi: 10.3389/fcell.2020.00355.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.00355</ArticleId><ArticleId IdType="pmc">PMC7243138</ArticleId><ArticleId IdType="pubmed">32500074</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankovic J. Parkinson&#x2019;s disease: Clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry. 2008;79:368&#x2013;376. doi: 10.1136/jnnp.2007.131045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2007.131045</ArticleId><ArticleId IdType="pubmed">18344392</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauer W., Przedborski S. Parkinson&#x2019;s disease: Mechanisms and models. Neuron. 2003;39:889&#x2013;909. doi: 10.1016/S0896-6273(03)00568-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00568-3</ArticleId><ArticleId IdType="pubmed">12971891</ArticleId></ArticleIdList></Reference><Reference><Citation>Cookson M.R. The biochemistry of parkinson&#x2019;s disease. Annu. Rev. Biochem. 2005;74:29&#x2013;52. doi: 10.1146/annurev.biochem.74.082803.133400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.74.082803.133400</ArticleId><ArticleId IdType="pubmed">15952880</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidhu A., Wersinger C., Moussa C.E., Vernier P. The role of alpha-synuclein in both neuroprotection and neurodegeneration. Ann. N. Y. Acad. Sci. 2004;1035:250&#x2013;270. doi: 10.1196/annals.1332.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1332.016</ArticleId><ArticleId IdType="pubmed">15681812</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller D.W., Hague S.M., Clarimon J., Baptista M., Gwinn-Hardy K., Cookson M.R., Singleton A.B. Alpha-synuclein in blood and brain from familial parkinson disease with snca locus triplication. Neurology. 2004;62:1835&#x2013;1838. doi: 10.1212/01.WNL.0000127517.33208.F4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000127517.33208.F4</ArticleId><ArticleId IdType="pubmed">15159488</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. Alpha-synuclein in filamentous inclusions of lewy bodies from parkinson&#x2019;s disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA. 1998;95:6469&#x2013;6473. doi: 10.1073/pnas.95.11.6469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.11.6469</ArticleId><ArticleId IdType="pmc">PMC27806</ArticleId><ArticleId IdType="pubmed">9600990</ArticleId></ArticleIdList></Reference><Reference><Citation>Singhal N.K., Srivastava G., Patel D.K., Jain S.K., Singh M.P. Melatonin or silymarin reduces maneb- and paraquat-induced parkinson&#x2019;s disease phenotype in the mouse. J. Pineal Res. 2011;50:97&#x2013;109. doi: 10.1111/j.1600-079X.2010.00819.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2010.00819.x</ArticleId><ArticleId IdType="pubmed">20964710</ArticleId></ArticleIdList></Reference><Reference><Citation>Patki G., Lau Y.S. Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of parkinson&#x2019;s disease. Pharmacol. Biochem. Behav. 2011;99:704&#x2013;711. doi: 10.1016/j.pbb.2011.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbb.2011.06.026</ArticleId><ArticleId IdType="pmc">PMC3156390</ArticleId><ArticleId IdType="pubmed">21741988</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xfc;ger R., Kuhn W., M&#xfc;ller T., Woitalla D., Graeber M., K&#xf6;sel S., Przuntek H., Epplen J.T., Sch&#xf6;ls L., Riess O. Ala30pro mutation in the gene encoding alpha-synuclein in parkinson&#x2019;s disease. Nat. Genet. 1998;18:106&#x2013;108. doi: 10.1038/ng0298-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0298-106</ArticleId><ArticleId IdType="pubmed">9462735</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito-Armas J.M., Baekelandt V., Castro-Hern&#xe1;ndez J.R., Gonz&#xe1;lez-Hern&#xe1;ndez T., Rodr&#xed;guez M., Castro R. Melatonin prevents dopaminergic cell loss induced by lentiviral vectors expressing a30p mutant alpha-synuclein. Histol. Histopathol. 2013;28:999&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pubmed">23444197</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.F., Huang H.J., Lee H.C., Hung K.C., Wu R.T., Lin A.M. Melatonin attenuates kainic acid-induced neurotoxicity in mouse hippocampus via inhibition of autophagy and &#x3b1;-synuclein aggregation. J. Pineal Res. 2012;52:312&#x2013;321. doi: 10.1111/j.1600-079X.2011.00945.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2011.00945.x</ArticleId><ArticleId IdType="pubmed">22212051</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin A.M., Fang S.F., Chao P.L., Yang C.H. Melatonin attenuates arsenite-induced apoptosis in rat brain: Involvement of mitochondrial and endoplasmic reticulum pathways and aggregation of alpha-synuclein. J. Pineal Res. 2007;43:163&#x2013;171. doi: 10.1111/j.1600-079X.2007.00456.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2007.00456.x</ArticleId><ArticleId IdType="pubmed">17645694</ArticleId></ArticleIdList></Reference><Reference><Citation>Su L.Y., Li H., Lv L., Feng Y.M., Li G.D., Luo R., Zhou H.J., Lei X.G., Ma L., Li J.L., et al. Melatonin attenuates mptp-induced neurotoxicity via preventing cdk5-mediated autophagy and snca/&#x3b1;-synuclein aggregation. Autophagy. 2015;11:1745&#x2013;1759. doi: 10.1080/15548627.2015.1082020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2015.1082020</ArticleId><ArticleId IdType="pmc">PMC4824603</ArticleId><ArticleId IdType="pubmed">26292069</ArticleId></ArticleIdList></Reference><Reference><Citation>Sae-Ung K., U&#xe9;da K., Govitrapong P., Phansuwan-Pujito P. Melatonin reduces the expression of alpha-synuclein in the dopamine containing neuronal regions of amphetamine-treated postnatal rats. J. Pineal Res. 2012;52:128&#x2013;137. doi: 10.1111/j.1600-079X.2011.00927.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2011.00927.x</ArticleId><ArticleId IdType="pubmed">21851386</ArticleId></ArticleIdList></Reference><Reference><Citation>Zampol M.A., Barros M.H. Melatonin improves survival and respiratory activity of yeast cells challenged by alpha-synuclein and menadione. Yeast. 2018;35:281&#x2013;290. doi: 10.1002/yea.3296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/yea.3296</ArticleId><ArticleId IdType="pubmed">29143358</ArticleId></ArticleIdList></Reference><Reference><Citation>Adi N., Mash D.C., Ali Y., Singer C., Shehadeh L., Papapetropoulos S. Melatonin mt1 and mt2 receptor expression in parkinson&#x2019;s disease. Med. Sci. Monit. 2010;16:BR61&#x2013;BR67.</Citation><ArticleIdList><ArticleId IdType="pubmed">20110911</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis G.L. Parkinson&#x2019;s disease as a neuroendocrine disorder of circadian function: Dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process. Rev. Neurosci. 2008;19:245&#x2013;316. doi: 10.1515/REVNEURO.2008.19.4-5.245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/REVNEURO.2008.19.4-5.245</ArticleId><ArticleId IdType="pubmed">19145986</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexiuk N.A., Vriend J.P. Melatonin reduces dopamine content in the neurointermediate lobe of male syrian hamsters. Brain Res. Bull. 1993;32:433&#x2013;436. doi: 10.1016/0361-9230(93)90211-S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0361-9230(93)90211-S</ArticleId><ArticleId IdType="pubmed">8221133</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis G.L. The role of ml-23 and other melatonin analogues in the treatment and management of parkinson&#x2019;s disease. Drug News Perspect. 2005;18:437&#x2013;444. doi: 10.1358/dnp.2005.18.7.939349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1358/dnp.2005.18.7.939349</ArticleId><ArticleId IdType="pubmed">16362083</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis G.L. Intraocular microinjections repair experimental parkinson&#x2019;s disease. Brain Res. 2008;1217:119&#x2013;131. doi: 10.1016/j.brainres.2008.03.083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2008.03.083</ArticleId><ArticleId IdType="pubmed">18502399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross C.A., Tabrizi S.J. Huntington&#x2019;s disease: From molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10:83&#x2013;98. doi: 10.1016/S1474-4422(10)70245-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70245-3</ArticleId><ArticleId IdType="pubmed">21163446</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Burg J.M., Bj&#xf6;rkqvist M., Brundin P. Beyond the brain: Widespread pathology in huntington&#x2019;s disease. Lancet Neurol. 2009;8:765&#x2013;774. doi: 10.1016/S1474-4422(09)70178-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(09)70178-4</ArticleId><ArticleId IdType="pubmed">19608102</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawa A., Wiegand G.W., Cooper J., Margolis R.L., Sharp A.H., Lawler J.F.J., Greenamyre J.T., Snyder S.H., Ross C.A. Increased apoptosis of huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med. 1999;5:1194&#x2013;1198. doi: 10.1038/13518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/13518</ArticleId><ArticleId IdType="pubmed">10502825</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalliolia E., Silajd&#x17e;i&#x107; E., Nambron R., Hill N.R., Doshi A., Frost C., Watt H., Hindmarsh P., Bj&#xf6;rkqvist M., Warner T.T. Plasma melatonin is reduced in huntington&#x2019;s disease. Mov. Disord. 2014;29:1511&#x2013;1515. doi: 10.1002/mds.26003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26003</ArticleId><ArticleId IdType="pubmed">25164424</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue F., Shi C., Chen Q., Hang W., Xia L., Wu Y., Tao S.Z., Zhou J., Shi A., Chen J. Melatonin mediates protective effects against kainic acid-induced neuronal death through safeguarding er stress and mitochondrial disturbance. Front. Mol. Neurosci. 2017;10:49. doi: 10.3389/fnmol.2017.00049.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00049</ArticleId><ArticleId IdType="pmc">PMC5329003</ArticleId><ArticleId IdType="pubmed">28293167</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan D.X., Manchester L.C., Reiter R.J., Qi W., Kim S.J., El-Sokkary G.H. Melatonin protects hippocampal neurons in vivo against kainic acid-induced damage in mice. J. Neurosci. Res. 1998;54:382&#x2013;389. doi: 10.1002/(SICI)1097-4547(19981101)54:3&lt;382::AID-JNR9&gt;3.0.CO;2-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4547(19981101)54:3&lt;382::AID-JNR9&gt;3.0.CO;2-Y</ArticleId><ArticleId IdType="pubmed">9819143</ArticleId></ArticleIdList></Reference><Reference><Citation>Manev H., Uz T., Kharlamov A., Cagnoli C.M., Franceschini D., Giusti P. In vivo protection against kainate-induced apoptosis by the pineal hormone melatonin: Effect of exogenous melatonin and circadian rhythm. Restor. Neurol. Neurosci. 1996;9:251&#x2013;256. doi: 10.3233/RNN-1996-9408.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/RNN-1996-9408</ArticleId><ArticleId IdType="pubmed">21551914</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xfa;nez I., Montilla P., Del Carmen Mu&#xf1;oz M., Feij&#xf3;o M., Salcedo M. Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of huntington&#x2019;s disease. J. Pineal Res. 2004;37:252&#x2013;256. doi: 10.1111/j.1600-079X.2004.00163.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2004.00163.x</ArticleId><ArticleId IdType="pubmed">15485551</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam E., Lee S.M., Koh S.E., Joo W.S., Maeng S., Im H.I., Kim Y.S. Melatonin protects against neuronal damage induced by 3-nitropropionic acid in rat striatum. Brain Res. 2005;1046:90&#x2013;96. doi: 10.1016/j.brainres.2005.03.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2005.03.053</ArticleId><ArticleId IdType="pubmed">15882841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu S., Lin E., Liu B., Ma Y., OuYang L., Li Y., Chen S., Zhang J., Lei W. Melatonin reduces projection neuronal injury induced by 3-nitropropionic acid in the rat striatum. Neuro Degener. Dis. 2014;14:139&#x2013;150. doi: 10.1159/000365891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000365891</ArticleId><ArticleId IdType="pubmed">25342207</ArticleId></ArticleIdList></Reference><Reference><Citation>Mochel F., Haller R.G. Energy deficit in huntington disease: Why it matters. J. Clin. Investig. 2011;121:493&#x2013;499. doi: 10.1172/JCI45691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI45691</ArticleId><ArticleId IdType="pmc">PMC3026743</ArticleId><ArticleId IdType="pubmed">21285522</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Sirianni A., Pei Z., Cormier K., Smith K., Jiang J., Zhou S., Wang H., Zhao R., Yano H., et al. The melatonin mt1 receptor axis modulates mutant huntingtin-mediated toxicity. J. Neurosci. 2011;31:14496&#x2013;14507. doi: 10.1523/JNEUROSCI.3059-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3059-11.2011</ArticleId><ArticleId IdType="pmc">PMC3213696</ArticleId><ArticleId IdType="pubmed">21994366</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Li F., Su X., Li Y., Wang Y., Fang R., Guo Y., Jin T., Shan H., Zhao X., et al. Melatonin prevents lung injury by regulating apelin 13 to improve mitochondrial dysfunction. Exp. Mol. Med. 2019;51:1&#x2013;12. doi: 10.1038/s12276-019-0273-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-019-0273-8</ArticleId><ArticleId IdType="pmc">PMC6802616</ArticleId><ArticleId IdType="pubmed">31273199</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz A., Matute C., Alberdi E. Intracellular ca2+ release through ryanodine receptors contributes to ampa receptor-mediated mitochondrial dysfunction and er stress in oligodendrocytes. Cell Death Dis. 2010;1:e54. doi: 10.1038/cddis.2010.31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2010.31</ArticleId><ArticleId IdType="pmc">PMC3032558</ArticleId><ArticleId IdType="pubmed">21364659</ArticleId></ArticleIdList></Reference><Reference><Citation>Bano D., Zanetti F., Mende Y., Nicotera P. Neurodegenerative processes in huntington&#x2019;s disease. Cell Death Dis. 2011;2:e228. doi: 10.1038/cddis.2011.112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2011.112</ArticleId><ArticleId IdType="pmc">PMC3223696</ArticleId><ArticleId IdType="pubmed">22071633</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung A.W., Halestrap A.P. Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. Biochim. Biophys. Acta. 2008;1777:946&#x2013;952. doi: 10.1016/j.bbabio.2008.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbabio.2008.03.009</ArticleId><ArticleId IdType="pubmed">18407825</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrabi S.A., Sayeed I., Siemen D., Wolf G., Horn T.F. Direct inhibition of the mitochondrial permeability transition pore: A possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2004;18:869&#x2013;871. doi: 10.1096/fj.03-1031fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.03-1031fje</ArticleId><ArticleId IdType="pubmed">15033929</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X. The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci. Ther. 2009;15:345&#x2013;357. doi: 10.1111/j.1755-5949.2009.00105.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-5949.2009.00105.x</ArticleId><ArticleId IdType="pmc">PMC2846661</ArticleId><ArticleId IdType="pubmed">19818070</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohseni M., Mihandoost E., Shirazi A., Sepehrizadeh Z., Bazzaz J.T., Ghazi-khansari M. Melatonin may play a role in modulation of bax and bcl-2 expression levels to protect rat peripheral blood lymphocytes from gamma irradiation-induced apoptosis. Mutat. Res. 2012;738&#x2013;739:19&#x2013;27. doi: 10.1016/j.mrfmmm.2012.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mrfmmm.2012.08.006</ArticleId><ArticleId IdType="pubmed">22982225</ArticleId></ArticleIdList></Reference><Reference><Citation>Radogna F., Cristofanon S., Paternoster L., D&#x2019;Alessio M., De Nicola M., Cerella C., Dicato M., Diederich M., Ghibelli L. Melatonin antagonizes the intrinsic pathway of apoptosis via mitochondrial targeting of bcl-2. J. Pineal Res. 2008;44:316&#x2013;325. doi: 10.1111/j.1600-079X.2007.00532.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2007.00532.x</ArticleId><ArticleId IdType="pubmed">18339127</ArticleId></ArticleIdList></Reference><Reference><Citation>Radogna F., Albertini M.C., De Nicola M., Diederich M., Bejarano I., Ghibelli L. Melatonin promotes bax sequestration to mitochondria reducing cell susceptibility to apoptosis via the lipoxygenase metabolite 5-hydroxyeicosatetraenoic acid. Mitochondrion. 2015;21:113&#x2013;121. doi: 10.1016/j.mito.2015.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2015.02.003</ArticleId><ArticleId IdType="pubmed">25702644</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi N., Razavi S., Nikzad E. Multiple sclerosis: Pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J. 2017;19:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5241505</ArticleId><ArticleId IdType="pubmed">28367411</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamm C.P., Uitdehaag B.M., Polman C.H. Multiple sclerosis: Current knowledge and future outlook. Eur. Neurol. 2014;72:132&#x2013;141. doi: 10.1159/000360528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000360528</ArticleId><ArticleId IdType="pubmed">25095894</ArticleId></ArticleIdList></Reference><Reference><Citation>Wootla B., Eriguchi M., Rodriguez M. Is multiple sclerosis an autoimmune disease? Autoimmune Dis. 2012;2012:969657. doi: 10.1155/2012/969657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/969657</ArticleId><ArticleId IdType="pmc">PMC3361990</ArticleId><ArticleId IdType="pubmed">22666554</ArticleId></ArticleIdList></Reference><Reference><Citation>Compston A., Coles A. Multiple sclerosis. Lancet. 2008;372:1502&#x2013;1517. doi: 10.1016/S0140-6736(08)61620-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(08)61620-7</ArticleId><ArticleId IdType="pubmed">18970977</ArticleId></ArticleIdList></Reference><Reference><Citation>Akpinar Z., Tokg&#xf6;z S., G&#xf6;kbel H., Okudan N., U&#x11f;uz F., Yilmaz G. The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis. Psychiatry Res. 2008;161:253&#x2013;257. doi: 10.1016/j.psychres.2007.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psychres.2007.11.022</ArticleId><ArticleId IdType="pubmed">18848732</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhadi N., Oryan S., Nabiuni M. Serum levels of melatonin and cytokines in multiple sclerosis. Biomed. J. 2014;37:90&#x2013;92. doi: 10.4103/2319-4170.125885.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2319-4170.125885</ArticleId><ArticleId IdType="pubmed">24732664</ArticleId></ArticleIdList></Reference><Reference><Citation>Damasceno A., Moraes A.S., Farias A., Damasceno B.P., dos Santos L.M., Cendes F. Disruption of melatonin circadian rhythm production is related to multiple sclerosis severity: A preliminary study. J. Neurol. Sci. 2015;353:166&#x2013;168. doi: 10.1016/j.jns.2015.03.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.03.040</ArticleId><ArticleId IdType="pubmed">25930714</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamud L., Golan D., Luboshitzky R., Lavi I., Miller A. Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. J. Neurol. Sci. 2012;314:37&#x2013;40. doi: 10.1016/j.jns.2011.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2011.11.003</ArticleId><ArticleId IdType="pubmed">22137446</ArticleId></ArticleIdList></Reference><Reference><Citation>Abo Taleb H.A., Alghamdi B.S. Neuroprotective effects of melatonin during demyelination and remyelination stages in a mouse model of multiple sclerosis. J. Mol. Neurosci. MN. 2020;70:386&#x2013;402. doi: 10.1007/s12031-019-01425-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-019-01425-6</ArticleId><ArticleId IdType="pubmed">31713152</ArticleId></ArticleIdList></Reference><Reference><Citation>Vakilzadeh G., Khodagholi F., Ghadiri T., Ghaemi A., Noorbakhsh F., Sharifzadeh M., Gorji A. The effect of melatonin on behavioral, molecular, and histopathological changes in cuprizone model of demyelination. Mol. Neurobiol. 2016;53:4675&#x2013;4684. doi: 10.1007/s12035-015-9404-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9404-y</ArticleId><ArticleId IdType="pubmed">26310973</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashani I.R., Rajabi Z., Akbari M., Hassanzadeh G., Mohseni A., Eramsadati M.K., Rafiee K., Beyer C., Kipp M., Zendedel A. Protective effects of melatonin against mitochondrial injury in a mouse model of multiple sclerosis. Exp. Brain Res. 2014;232:2835&#x2013;2846. doi: 10.1007/s00221-014-3946-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00221-014-3946-5</ArticleId><ArticleId IdType="pubmed">24798398</ArticleId></ArticleIdList></Reference><Reference><Citation>Mascanfroni I.D., Yeste A., Vieira S.M., Burns E.J., Patel B., Sloma I., Wu Y., Mayo L., Ben-Hamo R., Efroni S., et al. Il-27 acts on dcs to suppress the t cell response and autoimmunity by inducing expression of the immunoregulatory molecule cd39. Nat. Immunol. 2013;14:1054&#x2013;1063. doi: 10.1038/ni.2695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2695</ArticleId><ArticleId IdType="pmc">PMC3964005</ArticleId><ArticleId IdType="pubmed">23995234</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc1;lvarez-S&#xe1;nchez N., Cruz-Chamorro I., D&#xed;az-S&#xe1;nchez M., Sarmiento-Soto H., Medrano-Campillo P., Mart&#xed;nez-L&#xf3;pez A., Lardone P.J., Guerrero J.M., Carrillo-Vico A. Melatonin reduces inflammatory response in peripheral t helper lymphocytes from relapsing-remitting multiple sclerosis patients. J. Pineal Res. 2017;63:e12442. doi: 10.1111/jpi.12442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12442</ArticleId><ArticleId IdType="pubmed">28793364</ArticleId></ArticleIdList></Reference><Reference><Citation>Farez M.F., Mascanfroni I.D., M&#xe9;ndez-Huergo S.P., Yeste A., Murugaiyan G., Garo L.P., Balbuena Aguirre M.E., Patel B., Ysrraelit M.C., Zhu C., et al. Melatonin contributes to the seasonality of multiple sclerosis relapses. Cell. 2015;162:1338&#x2013;1352. doi: 10.1016/j.cell.2015.08.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.08.025</ArticleId><ArticleId IdType="pmc">PMC4570563</ArticleId><ArticleId IdType="pubmed">26359987</ArticleId></ArticleIdList></Reference><Reference><Citation>von Lewinski F., Keller B.U. Ca2+, mitochondria and selective motoneuron vulnerability: Implications for als. Trends Neurosci. 2005;28:494&#x2013;500. doi: 10.1016/j.tins.2005.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2005.07.001</ArticleId><ArticleId IdType="pubmed">16026864</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Cook A., Kim J., Baranov S.V., Jiang J., Smith K., Cormier K., Bennett E., Browser R.P., Day A.L., et al. Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits mt1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2013;55:26&#x2013;35. doi: 10.1016/j.nbd.2013.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.03.008</ArticleId><ArticleId IdType="pmc">PMC3652329</ArticleId><ArticleId IdType="pubmed">23537713</ArticleId></ArticleIdList></Reference><Reference><Citation>Rog&#xe9;rio F., Teixeira S.A., de Rezende A.C., de S&#xe1; R.C., de Souza Queiroz L., De Nucci G., Muscar&#xe1; M.N., Langone F. Superoxide dismutase isoforms 1 and 2 in lumbar spinal cord of neonatal rats after sciatic nerve transection and melatonin treatment. Brain Res. Dev. Brain Res. 2005;154:217&#x2013;225. doi: 10.1016/j.devbrainres.2004.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devbrainres.2004.10.017</ArticleId><ArticleId IdType="pubmed">15707675</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano A., Donnenfeld H., Sasaki S., Nakano I. Fine structural observations of neurofilamentous changes in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 1984;43:461&#x2013;470. doi: 10.1097/00005072-198409000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-198409000-00001</ArticleId><ArticleId IdType="pubmed">6540799</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouleau G.A., Clark A.W., Rooke K., Pramatarova A., Krizus A., Suchowersky O., Julien J.P., Figlewicz D. Sod1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis. Ann. Neurol. 1996;39:128&#x2013;131. doi: 10.1002/ana.410390119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410390119</ArticleId><ArticleId IdType="pubmed">8572658</ArticleId></ArticleIdList></Reference><Reference><Citation>Julien J.P., Beaulieu J.M. Cytoskeletal abnormalities in amyotrophic lateral sclerosis: Beneficial or detrimental effects? J. Neurol. Sci. 2000;180:7&#x2013;14. doi: 10.1016/S0022-510X(00)00422-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(00)00422-6</ArticleId><ArticleId IdType="pubmed">11090858</ArticleId></ArticleIdList></Reference><Reference><Citation>Est&#xe9;vez A.G., Crow J.P., Sampson J.B., Reiter C., Zhuang Y., Richardson G.J., Tarpey M.M., Barbeito L., Beckman J.S. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science. 1999;286:2498&#x2013;2500.</Citation><ArticleIdList><ArticleId IdType="pubmed">10617463</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow J.P., Sampson J.B., Zhuang Y., Thompson J.A., Beckman J.S. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J. Neurochem. 1997;69:1936&#x2013;1944. doi: 10.1046/j.1471-4159.1997.69051936.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1997.69051936.x</ArticleId><ArticleId IdType="pubmed">9349538</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiavon A.P., Soares L.M., Bonato J.M., Milani H., Guimar&#xe3;es F.S., Weffort de Oliveira R.M. Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice. Neurotox. Res. 2014;26:307&#x2013;316. doi: 10.1007/s12640-014-9457-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-014-9457-0</ArticleId><ArticleId IdType="pubmed">24532152</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer J.S., Rauch G., Rauch R.A., Haque A. Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. Neurobiol. Aging. 2000;21:161&#x2013;169. doi: 10.1016/S0197-4580(00)00136-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(00)00136-6</ArticleId><ArticleId IdType="pubmed">10867201</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria R.N., Maestre G.E., Arizaga R., Friedland R.P., Galasko D., Hall K., Luchsinger J.A., Ogunniyi A., Perry E.K., Potocnik F., et al. Alzheimer&#x2019;s disease and vascular dementia in developing countries: Prevalence, management, and risk factors. Lancet Neurol. 2008;7:812&#x2013;826. doi: 10.1016/S1474-4422(08)70169-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70169-8</ArticleId><ArticleId IdType="pmc">PMC2860610</ArticleId><ArticleId IdType="pubmed">18667359</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimo A., Guerchet M., Ali G.C., Wu Y.T., Prina A.M., Winblad B., J&#xf6;nsson L., Liu Z., Prince M. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimer&#x2019;s Dement. 2017;13:1&#x2013;7. doi: 10.1016/j.jalz.2016.07.150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.07.150</ArticleId><ArticleId IdType="pmc">PMC5232417</ArticleId><ArticleId IdType="pubmed">27583652</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi Y., Wang M., Zhang W., Bai M., Du Y., Zhang Z., Li Z., Miao J. Neuronal damage, central cholinergic dysfunction and oxidative damage correlate with cognitive deficits in rats with chronic cerebral hypoperfusion. Neurobiol. Learn. Mem. 2014;109:7&#x2013;19. doi: 10.1016/j.nlm.2013.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nlm.2013.11.016</ArticleId><ArticleId IdType="pubmed">24315928</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S., Singh P., Sharma B.M., Sharma B. Neuroprotective effects of agomelatine and vinpocetine against chronic cerebral hypoperfusion induced vascular dementia. Curr. Neurovascular Res. 2015;12:240&#x2013;252. doi: 10.2174/1567202612666150603130235.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567202612666150603130235</ArticleId><ArticleId IdType="pubmed">26036976</ArticleId></ArticleIdList></Reference><Reference><Citation>Bin-Jaliah I., Sakr H.F. Melatonin ameliorates brain oxidative stress and upregulates senescence marker protein-30 and osteopontin in a rat model of vascular dementia. Physiol. Int. 2018;105:38&#x2013;52. doi: 10.1556/2060.105.2018.1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1556/2060.105.2018.1.1</ArticleId><ArticleId IdType="pubmed">29602294</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali D.P., Nagle C.A., Freire F., Rosner J.M. Effects of melatonin on neurotransmitter uptake and release by synaptosome-rich homogenates of the rat hypothalamus. Neuroendocrinology. 1975;18:72&#x2013;85. doi: 10.1159/000122385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000122385</ArticleId><ArticleId IdType="pubmed">238164</ArticleId></ArticleIdList></Reference><Reference><Citation>Niizuma K., Endo H., Chan P.H. Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. J. Neurochem. 2009;109(Suppl. S1):133&#x2013;138. doi: 10.1111/j.1471-4159.2009.05897.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.05897.x</ArticleId><ArticleId IdType="pmc">PMC2679225</ArticleId><ArticleId IdType="pubmed">19393019</ArticleId></ArticleIdList></Reference><Reference><Citation>Das A., McDowell M., Pava M.J., Smith J.A., Reiter R.J., Woodward J.J., Varma A.K., Ray S.K., Banik N.L. The inhibition of apoptosis by melatonin in vsc4.1 motoneurons exposed to oxidative stress, glutamate excitotoxicity, or tnf-alpha toxicity involves membrane melatonin receptors. J. Pineal Res. 2010;48:157&#x2013;169. doi: 10.1111/j.1600-079X.2009.00739.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2009.00739.x</ArticleId><ArticleId IdType="pmc">PMC2862889</ArticleId><ArticleId IdType="pubmed">20082663</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali T., Badshah H., Kim T.H., Kim M.O. Melatonin attenuates d-galactose-induced memory impairment, neuroinflammation and neurodegeneration via rage/nf-k b/jnk signaling pathway in aging mouse model. J. Pineal Res. 2015;58:71&#x2013;85. doi: 10.1111/jpi.12194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12194</ArticleId><ArticleId IdType="pubmed">25401971</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauriz J.L., Collado P.S., Veneroso C., Reiter R.J., Gonz&#xe1;lez-Gallego J. A review of the molecular aspects of melatonin&#x2019;s anti-inflammatory actions: Recent insights and new perspectives. J. Pineal Res. 2013;54:1&#x2013;14. doi: 10.1111/j.1600-079X.2012.01014.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2012.01014.x</ArticleId><ArticleId IdType="pubmed">22725668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigami A., Handa S., Maruyama N., Supakar P.C. Nuclear localization of senescence marker protein-30, smp30, in cultured mouse hepatocytes and its similarity to rna polymerase. Biosci. Biotechnol. Biochem. 2003;67:158&#x2013;160. doi: 10.1271/bbb.67.158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1271/bbb.67.158</ArticleId><ArticleId IdType="pubmed">12619687</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun S.P., Han Y.S., Lee J.H., Kim S.M., Lee S.H. Melatonin rescues mesenchymal stem cells from senescence induced by the uremic toxin p-cresol via inhibiting mtor-dependent autophagy. Biomol. Ther. 2018;26:389&#x2013;398. doi: 10.4062/biomolther.2017.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.4062/biomolther.2017.071</ArticleId><ArticleId IdType="pmc">PMC6029684</ArticleId><ArticleId IdType="pubmed">28655071</ArticleId></ArticleIdList></Reference><Reference><Citation>Meller R., Stevens S.L., Minami M., Cameron J.A., King S., Rosenzweig H., Doyle K., Lessov N.S., Simon R.P., Stenzel-Poore M.P. Neuroprotection by osteopontin in stroke. J. Cereb. Blood Flow Metab. 2005;25:217&#x2013;225. doi: 10.1038/sj.jcbfm.9600022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.jcbfm.9600022</ArticleId><ArticleId IdType="pubmed">15678124</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H., Ayer R., Sugawara T., Chen W., Sozen T., Hasegawa Y., Kanamaru K., Zhang J.H. Protective effects of recombinant osteopontin on early brain injury after subarachnoid hemorrhage in rats. Crit. Care Med. 2010;38:612&#x2013;618. doi: 10.1097/CCM.0b013e3181c027ae.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181c027ae</ArticleId><ArticleId IdType="pmc">PMC2808465</ArticleId><ArticleId IdType="pubmed">19851092</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Ma Q., Suzuki H., Hartman R., Tang J., Zhang J.H. Osteopontin reduced hypoxia-ischemia neonatal brain injury by suppression of apoptosis in a rat pup model. Stroke. 2011;42:764&#x2013;769. doi: 10.1161/STROKEAHA.110.599118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.110.599118</ArticleId><ArticleId IdType="pmc">PMC3045536</ArticleId><ArticleId IdType="pubmed">21273567</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Jiang S., Dong Y., Fan C., Zhao L., Yang X., Li J., Di S., Yue L., Liang G., et al. Melatonin prevents cell death and mitochondrial dysfunction via a sirt1-dependent mechanism during ischemic-stroke in mice. J. Pineal Res. 2015;58:61&#x2013;70. doi: 10.1111/jpi.12193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpi.12193</ArticleId><ArticleId IdType="pubmed">25401748</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z., Cheng Y., Zhang J.T. Long-term effects of melatonin or 17 beta-estradiol on improving spatial memory performance in cognitively impaired, ovariectomized adult rats. J. Pineal Res. 2004;37:198&#x2013;206. doi: 10.1111/j.1600-079X.2004.00158.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2004.00158.x</ArticleId><ArticleId IdType="pubmed">15357665</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen D., Tian X., Sang W., Song R. Effect of melatonin and resveratrol against memory impairment and hippocampal damage in a rat model of vascular dementia. Neuroimmunomodulation. 2016;23:318&#x2013;331. doi: 10.1159/000454681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000454681</ArticleId><ArticleId IdType="pubmed">28419991</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal G., Comprido D., Duarte C.B. Bdnf-induced local protein synthesis and synaptic plasticity. Neuropharmacology. 2014;76:639&#x2013;656. doi: 10.1016/j.neuropharm.2013.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2013.04.005</ArticleId><ArticleId IdType="pubmed">23602987</ArticleId></ArticleIdList></Reference><Reference><Citation>Ninan I. Synaptic regulation of affective behaviors; role of bdnf. Neuropharmacology. 2014;76:684&#x2013;695. doi: 10.1016/j.neuropharm.2013.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2013.04.011</ArticleId><ArticleId IdType="pmc">PMC3825795</ArticleId><ArticleId IdType="pubmed">23747574</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbesi M., Uz T., Dzitoyeva S., Manev H. Stimulatory effects of a melatonin receptor agonist, ramelteon, on bdnf in mouse cerebellar granule cells. Neurosci. Lett. 2008;439:34&#x2013;36. doi: 10.1016/j.neulet.2008.04.099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2008.04.099</ArticleId><ArticleId IdType="pubmed">18501512</ArticleId></ArticleIdList></Reference><Reference><Citation>Brusco L.I., M&#xe1;rquez M., Cardinali D.P. Monozygotic twins with alzheimer&#x2019;s disease treated with melatonin: Case report. J. Pineal Res. 1998;25:260&#x2013;263. doi: 10.1111/j.1600-079X.1998.tb00396.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.1998.tb00396.x</ArticleId><ArticleId IdType="pubmed">9885996</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachiyants N., Trinkle D., Son S.J., Kim K.Y. Sundown syndrome in persons with dementia: An update. Psychiatry Investig. 2011;8:275&#x2013;287. doi: 10.4306/pi.2011.8.4.275.</Citation><ArticleIdList><ArticleId IdType="doi">10.4306/pi.2011.8.4.275</ArticleId><ArticleId IdType="pmc">PMC3246134</ArticleId><ArticleId IdType="pubmed">22216036</ArticleId></ArticleIdList></Reference><Reference><Citation>Klaffke S., Staedt J. Sundowning and circadian rhythm disorders in dementia. Acta Neurol. Belg. 2006;106:168&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">17323834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammers M., Ahmed A.I. Melatonin for sundown syndrome and delirium in dementia: Is it effective? J. Am. Geriatrics Soc. 2013;61:1045&#x2013;1046. doi: 10.1111/jgs.12296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.12296</ArticleId><ArticleId IdType="pubmed">23772740</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson K.N., Jamieson S., Graham A.J., Shneerson J.M. Rem sleep behaviour disorder treated with melatonin in a patient with alzheimer&#x2019;s disease. Clin. Neurol. Neurosurg. 2008;110:492&#x2013;495. doi: 10.1016/j.clineuro.2008.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2008.01.004</ArticleId><ArticleId IdType="pubmed">18299172</ArticleId></ArticleIdList></Reference><Reference><Citation>Jean-Louis G., Zizi F., von Gizycki H., Taub H. Effects of melatonin in two individuals with alzheimer&#x2019;s disease. Percept. Mot. Ski. 1998;87:331&#x2013;339. doi: 10.2466/pms.1998.87.1.331.</Citation><ArticleIdList><ArticleId IdType="doi">10.2466/pms.1998.87.1.331</ArticleId><ArticleId IdType="pubmed">9760668</ArticleId></ArticleIdList></Reference><Reference><Citation>Wade A.G., Farmer M., Harari G., Fund N., Laudon M., Nir T., Frydman-Marom A., Zisapel N. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate alzheimer&#x2019;s disease: A 6-month, randomized, placebo-controlled, multicenter trial. Clin. Interv. Aging. 2014;9:947&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4069047</ArticleId><ArticleId IdType="pubmed">24971004</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves G.S., Carvalho A.F., de Amorim de Carvalho L., Sudo F.K., Siqueira-Neto J.I., Oertel-Knochel V., Jurcoane A., Knochel C., Boecker H., Laks J., et al. Neuroimaging findings related to behavioral disturbances in alzheimer&#x2019;s disease: A systematic review. Curr. Alzheimer Res. 2017;14:61&#x2013;75. doi: 10.2174/1567205013666160603010203.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205013666160603010203</ArticleId><ArticleId IdType="pubmed">27298146</ArticleId></ArticleIdList></Reference><Reference><Citation>Serfaty M., Kennell-Webb S., Warner J., Blizard R., Raven P. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int. J. Geriatr. Psychiatry. 2002;17:1120&#x2013;1127. doi: 10.1002/gps.760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.760</ArticleId><ArticleId IdType="pubmed">12461760</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer C., Tractenberg R.E., Kaye J., Schafer K., Gamst A., Grundman M., Thomas R., Thal L.J. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in alzheimer&#x2019;s disease. Sleep. 2003;26:893&#x2013;901. doi: 10.1093/sleep/26.7.893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/sleep/26.7.893</ArticleId><ArticleId IdType="pmc">PMC4418658</ArticleId><ArticleId IdType="pubmed">14655926</ArticleId></ArticleIdList></Reference><Reference><Citation>Asayama K., Yamadera H., Ito T., Suzuki H., Kudo Y., Endo S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in alzheimer type dementia. J. Nippon Med. Sch. 2003;70:334&#x2013;341. doi: 10.1272/jnms.70.334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1272/jnms.70.334</ArticleId><ArticleId IdType="pubmed">12928714</ArticleId></ArticleIdList></Reference><Reference><Citation>Fainstein I., Bonetto A.J., Brusco L.I., Cardinali D.P. Effects of melatonin in elderly patients with sleep disturbance: A pilot study. Curr. Ther. Res. 1997;58:990&#x2013;1000. doi: 10.1016/S0011-393X(97)80066-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0011-393X(97)80066-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J., Garfinkel D., Lipson S. Melatonin for treatment of sundowning in elderly persons with dementia&#x2014;A preliminary study. Arch. Gerontol Geriatr. 2000;31:65&#x2013;76. doi: 10.1016/S0167-4943(00)00068-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0167-4943(00)00068-6</ArticleId><ArticleId IdType="pubmed">10989165</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishima K., Okawa M., Hozumi S., Hishikawa Y. Supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest-activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons. Chronobiol. Int. 2000;17:419&#x2013;432. doi: 10.1081/CBI-100101055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1081/CBI-100101055</ArticleId><ArticleId IdType="pubmed">10841214</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali D.P., Brusco L.I., Liberczuk C., Furio A.M. The use of melatonin in alzheimer&#x2019;s disease. Neuro Endocrinol. Lett. 2002;23(Suppl. S1):20&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">12019347</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahlberg R., Walther S. Actigraphy in agitated patients with dementia. Monitoring treatment outcomes. Z. Gerontol. Geriatr. 2007;40:178&#x2013;184. doi: 10.1007/s00391-007-0420-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00391-007-0420-z</ArticleId><ArticleId IdType="pubmed">17565435</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali D.P., Furio A.M., Brusco L.I. Clinical aspects of melatonin intervention in alzheimer&#x2019;s disease progression. Curr. Neuropharmacol. 2010;8:218&#x2013;227. doi: 10.2174/157015910792246209.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157015910792246209</ArticleId><ArticleId IdType="pmc">PMC3001215</ArticleId><ArticleId IdType="pubmed">21358972</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinali D.P., Vigo D.E., Olivar N., Vidal M.F., Brusco L.I. Melatonin therapy in patients with alzheimer&#x2019;s disease. Antioxidants. 2014;3:245&#x2013;277. doi: 10.3390/antiox3020245.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox3020245</ArticleId><ArticleId IdType="pmc">PMC4665493</ArticleId><ArticleId IdType="pubmed">26784870</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jonghe A., Korevaar J.C., van Munster B.C., de Rooij S.E. Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. Int. J. Geriatr. Psychiatry. 2010;25:1201&#x2013;1208. doi: 10.1002/gps.2454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/gps.2454</ArticleId><ArticleId IdType="pubmed">21086534</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Barcelo E.J., Rueda N., Mediavilla M.D., Martinez-Cue C., Reiter R.J. Clinical uses of melatonin in neurological diseases and mental and behavioural disorders. Curr. Med. Chem. 2017;24:3851&#x2013;3878. doi: 10.2174/0929867324666170718105557.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867324666170718105557</ArticleId><ArticleId IdType="pubmed">28721826</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandi-Perumal S.R., BaHammam A.S., Brown G.M., Spence D.W., Bharti V.K., Kaur C., Hardeland R., Cardinali D.P. Melatonin antioxidative defense: Therapeutical implications for aging and neurodegenerative processes. Neurotox. Res. 2013;23:267&#x2013;300. doi: 10.1007/s12640-012-9337-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-012-9337-4</ArticleId><ArticleId IdType="pubmed">22739839</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowling G.A., Burr R.L., Van Someren E.J., Hubbard E.M., Luxenberg J.S., Mastick J., Cooper B.A. Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with alzheimer&#x2019;s disease. J. Am. Geriatr. Soc. 2008;56:239&#x2013;246. doi: 10.1111/j.1532-5415.2007.01543.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2007.01543.x</ArticleId><ArticleId IdType="pmc">PMC2642966</ArticleId><ArticleId IdType="pubmed">18070004</ArticleId></ArticleIdList></Reference><Reference><Citation>Riemersma-van der Lek R.F., Swaab D.F., Twisk J., Hol E.M., Hoogendijk W.J., Van Someren E.J. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: A randomized controlled trial. JAMA. 2008;299:2642&#x2013;2655. doi: 10.1001/jama.299.22.2642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.299.22.2642</ArticleId><ArticleId IdType="pubmed">18544724</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordet R., Devos D., Brique S., Touitou Y., Guieu J.D., Libersa C., Dest&#xe9;e A. Study of circadian melatonin secretion pattern at different stages of parkinson&#x2019;s disease. Clin. Neuropharmacol. 2003;26:65&#x2013;72. doi: 10.1097/00002826-200303000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002826-200303000-00005</ArticleId><ArticleId IdType="pubmed">12671525</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowling G.A., Mastick J., Colling E., Carter J.H., Singer C.M., Aminoff M.J. Melatonin for sleep disturbances in parkinson&#x2019;s disease. Sleep Med. 2005;6:459&#x2013;466. doi: 10.1016/j.sleep.2005.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2005.04.004</ArticleId><ArticleId IdType="pubmed">16084125</ArticleId></ArticleIdList></Reference><Reference><Citation>Medeiros C.A., Carvalhedo de Bruin P.F., Lopes L.A., Magalh&#xe3;es M.C., de Lourdes Seabra M., de Bruin V.M. Effect of exogenous melatonin on sleep and motor dysfunction in parkinson&#x2019;s disease. A randomized, double blind, placebo-controlled study. J. Neurol. 2007;254:459&#x2013;464. doi: 10.1007/s00415-006-0390-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-006-0390-x</ArticleId><ArticleId IdType="pubmed">17404779</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowling G., Mastick J., Aminoff M. Melatonin for sleep disturbances in parkinson&#x2019;s disease: A pilot study. Sleep Res. Online. 2003;5:99&#x2013;103.</Citation></Reference><Reference><Citation>Litvinenko I.V., Krasakov I.V., Tikhomirova O.V. [sleep disorders in parkinson&#x2019;s disease without dementia: A comparative randomized controlled study of melatonin and clonazepam] Zhurnal Nevrologii Psikhiatrii Imeni S.S. Korsakova. 2012;112:26&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">23388588</ArticleId></ArticleIdList></Reference><Reference><Citation>Datieva V.K., Rosinskaia A.V., Levin O.S. [the use of melatonin in the treatment of chronic fatigue syndrome and circadian rhythm disorders in parkinson&#x2019;s disease] Zhurnal Nevrologii Psikhiatrii Imeni S.S. Korsakova. 2013;113:77&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">23994935</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob S., Poeggeler B., Weishaupt J.H., Sir&#xe9;n A.L., Hardeland R., B&#xe4;hr M., Ehrenreich H. Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (als): High tolerability of daily oral melatonin administration in als patients. J. Pineal Res. 2002;33:186&#x2013;187. doi: 10.1034/j.1600-079X.2002.02943.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-079X.2002.02943.x</ArticleId><ArticleId IdType="pubmed">12220335</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamczyk-Sowa M., Pierzchala K., Sowa P., Polaniak R., Kukla M., Hartel M. Influence of melatonin supplementation on serum antioxidative properties and impact of the quality of life in multiple sclerosis patients. J. Physiol. Pharmacol. 2014;65:543&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">25179086</ArticleId></ArticleIdList></Reference><Reference><Citation>Skarlis C., Anagnostouli M. The role of melatonin in multiple sclerosis. Neurol. Sci. 2020;41:769&#x2013;781. doi: 10.1007/s10072-019-04137-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-04137-2</ArticleId><ArticleId IdType="pubmed">31845043</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardeland R. Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment. Aging Dis. 2012;3:194&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3377831</ArticleId><ArticleId IdType="pubmed">22724080</ArticleId></ArticleIdList></Reference><Reference><Citation>Turek F.W., Gillette M.U. Melatonin, sleep, and circadian rhythms: Rationale for development of specific melatonin agonists. Sleep Med. 2004;5:523&#x2013;532. doi: 10.1016/j.sleep.2004.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sleep.2004.07.009</ArticleId><ArticleId IdType="pubmed">15511698</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardeland R. Investigational melatonin receptor agonists. Expert Opin. Investig. Drugs. 2010;19:747&#x2013;764. doi: 10.1517/13543784.2010.482926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543784.2010.482926</ArticleId><ArticleId IdType="pubmed">20408738</ArticleId></ArticleIdList></Reference><Reference><Citation>Spadoni G., Bedini A., Rivara S., Mor M. Melatonin receptor agonists: New options for insomnia and depression treatment. CNS Neurosci. Ther. 2011;17:733&#x2013;741. doi: 10.1111/j.1755-5949.2010.00197.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-5949.2010.00197.x</ArticleId><ArticleId IdType="pmc">PMC6493855</ArticleId><ArticleId IdType="pubmed">21554566</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>